CARGO THERAPEUTICS INC (CRGX)

Company Profile

Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. The company is headquartered in San Carlos, California and currently employs 116 full-time employees. The company went IPO on 2023-11-10. The firm is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company’s lead program, firicabtagene autoleucel (CRG-022), is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate. The firm is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The firm is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.

Company Info

CARGO THERAPEUTICS INC

835 Industrial Road, Suite 400

San Carlos CALIFORNIA

P: 16504998950

Employees: 150

Website: https://cargo-tx.com